title: Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients.
abstract: OBJECTIVE
  To assess the safety and efficacy of dendritic cell vaccination in metastatic uveal melanoma.
  
  
  METHODS
  Interventional case series.
  
  
  METHODS
  We analyzed 14 patients with metastatic uveal melanoma treated with dendritic cell vaccination. Patients with metastatic uveal melanoma received at least 3 vaccinations with autologous dendritic cells, professional antigen-presenting cells loaded with melanoma antigens gp100 and tyrosinase. The main outcome measures were safety, immunologic response, and overall survival.
  
  
  RESULTS
  Tumor-specific immune responses were induced with dendritic cell vaccination in 4 (29%) of 14 patients. Dendritic cell-vaccinated patients showed a median overall survival with metastatic disease of 19.2 months, relatively long compared with that reported in the literature. No severe treatment-related toxicities (common toxicity criteria grade 3 or 4) were observed.
  
  
  CONCLUSIONS
  Dendritic cell vaccination is feasible and safe in metastatic uveal melanoma. Dendritic cell-based immunotherapy is potent to enhance the host's antitumor immunity against uveal melanoma in approximately one third of patients. Compared with other prospective studies with similar inclusion criteria, dendritic cell vaccination may be associated with longer than average overall survival in patients with metastatic uveal melanoma.
authors.affiliation: Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, the Netherlands; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, the Netherlands.
authors.forename: Kalijn F
authors.initials: KF
authors.lastname: Bol
authors.affiliation: Department of Ophthalmology, Rotterdam Eye Hospital, Rotterdam, the Netherlands; Department of Clinical Genetics, Erasmus Medical Centre, Rotterdam, the Netherlands.
authors.forename: Hanneke W
authors.initials: HW
authors.lastname: Mensink
authors.affiliation: Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, the Netherlands; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, the Netherlands.
authors.forename: Erik H J G
authors.initials: EH
authors.lastname: Aarntzen
authors.affiliation: Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, the Netherlands.
authors.forename: Gerty
authors.initials: G
authors.lastname: Schreibelt
authors.affiliation: Department of Ophthalmology, Radboud University Medical Centre, Nijmegen, the Netherlands.
authors.forename: Jan E E
authors.initials: JE
authors.lastname: Keunen
authors.affiliation: De Duve Institute, Université Catholique de Louvain, Brussels, Belgium.
authors.forename: Pierre G
authors.initials: PG
authors.lastname: Coulie
authors.affiliation: Department of Clinical Genetics, Erasmus Medical Centre, Rotterdam, the Netherlands.
authors.forename: Annelies
authors.initials: A
authors.lastname: de Klein
authors.affiliation: Department of Medical Oncology, Academic Medical Center, Amsterdam, the Netherlands.
authors.forename: Cornelis J A
authors.initials: CJ
authors.lastname: Punt
authors.affiliation: Department of Ophthalmology, Rotterdam Eye Hospital, Rotterdam, the Netherlands.
authors.forename: Dion
authors.initials: D
authors.lastname: Paridaens
authors.affiliation: Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, the Netherlands.
authors.forename: Carl G
authors.initials: CG
authors.lastname: Figdor
authors.affiliation: Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, the Netherlands; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, the Netherlands. Electronic address: J.deVries@ncmls.ru.nl.
authors.forename: I Jolanda M
authors.initials: IJ
authors.lastname: de Vries
mesh_terms: D019496:Cancer Vaccines / Q000627:therapeutic use*; D003713:Dendritic Cells / Q000276:immunology*; D005500:Follow-Up Studies; D006801:Humans; D008545:Melanoma / Q000401:mortality* / Q000556:secondary / Q000628:therapy; D009362:Neoplasm Metastasis; D009426:Netherlands / Q000453:epidemiology; D011446:Prospective Studies; D015996:Survival Rate / Q000639:trends; D013997:Time Factors; D014604:Uveal Neoplasms / Q000401:mortality* / Q000556:secondary / Q000628:therapy; D014611:Vaccination / Q000379:methods*; D058951:gp100 Melanoma Antigen / Q000276:immunology*; D000098943:Uveal Melanoma
chemical_list: D019496:Cancer Vaccines; D058951:gp100 Melanoma Antigen